The 11th E-Bioindustry Exhibition (BIOCHINA 2026) was successfully held at Suzhou International Expo Center from March 12 to 14, 2026! With four major systems—Exhibition, Conference, Appointments, and Activities—this edition of the exhibition built a platform for exchange and cooperation in the biopharmaceutical industry.

 

With over 30,000 attendees representing more than 40 countries and regions, the event featured over 900 speakers who jointly organized more than 250 specialized forums, 11 invited closed-door meetings, and 31 brainstorming sessions. The 1-on-1 appointment system facilitated over 5,000 precise appointments. Meanwhile, over 400 exhibitors showcased thousands of products, connecting upstream and downstream supply-demand both domestically and internationally and sharing cutting-edge technological trends.

 

On-Site at the Conference

 

This event gathered elite experts from the global biopharmaceutical industry. As an animal model technology developer specializing in rapid and personalized customization services for various genetically modified model mice, MingCeler exhibited its TurboMice™ tetraploid compensation technology​ and gene-edited mouse model construction services.
 

At the exhibition, MingCeler's booth attracted numerous attendees to stop by and engage in discussions. Our Chairman, Marketing Director, Production Director, and regional sales managers engaged in in-depth discussions with professionals from various institutions and provided detailed answers to inquiries about technical details and application scenarios.

 

During these exchanges, the team focused on practical needs such as "rapid construction of complex animal models and efficiency improvement of new drug R&D pipelines", combined with the core advantages of TurboMice™ tetraploid compensation technology, and offered targeted solution ideas.

 

The on-site communication atmosphere was enthusiastic, with many attendees showing clear interest in the technology pathway and collaboration, and arranging follow-up specific connections.

 

 

 

 

 

 

MingCeler's TurboMice™ tetraploid compensation technology bypasses the time-consuming breeding and screening steps of conventional technologies, significantly shortening the modeling cycle and giving it a leading advantage globally. It can greatly support projects such as vaccine R&D, new drug development, precision medicine, and scientific research for emergency health events. Moreover, it provides the possibility of rapid preparation for the demand for complex animal models in disease research, promising to significantly advance related research progress in the life sciences field.

 

This participation not only demonstrated our technical strength but also deepened our connections with the global biopharmaceutical community.

 

Excitement never stops; we press on.​ MingCeler will continue to focus on the innovative R&D of the next-generation model animal preparation technology—TurboMice™ tetraploid compensation technology—providing higher-quality mouse models and customization services to empower the rapid development of the biopharmaceutical industry with innovative technology!